SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
Healthcare
$2.91 -0.53%
-$0.02 today
- Market cap
- $262.16M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
52W Low $1.85High $5.15
Volume 1.75M
Average 0.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$44.78M
FY 2025 · Annual
Investing Cash Flow
-$121.71M
FY 2025 · Annual
Financing Cash Flow
$168.30M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.14M) | (18.74M) | (42.19M) | (34.11M) | 13.27M |
| Depreciation & Amortization | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 2.67M | 2.42M | 2.94M | 5.21M |
| Change in Working Capital | 11.68M | (237.58K) | 2.33M | (2.3M) | (3.69M) |
| Accounts Receivables | 12.56M | 2.45M | 5.56M | (54.96K) | (891.83K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.94M) | (779.43K) | (2.7M) | 923.32K | 1.48M |
| Other Working Capital | 2.06M | (1.91M) | (528.64K) | (3.17M) | (4.28M) |
| Other Non-Cash Items | 3.48M | (10.45M) | 8.58M | (5.62M) | (62.66M) |
| Operating Cash Flow | 1.99M | (23.46M) | (25.12M) | (34.29M) | (44.78M) |
| Capital Expenditures | (10.94M) | (2.17M) | (197.15K) | (337.26K) | (933.15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 500 |
| Purchases of Investments | 0 | 0 | 0 | (37.45M) | (142.04M) |
| Sales of Investments | 0 | 0 | 0 | 25.82M | 21.26M |
| Other Investing Activities | 0 | 76.39K | 44.45K | 0 | 0 |
| Investing Cash Flow | (10.94M) | (2.09M) | (152.7K) | (11.96M) | (121.71M) |
| Debt Repayment | 1.54M | (1.19M) | (390.45K) | (907K) | (418.41K) |
| Common Stock Issued | 6.75K | 7.68M | 0 | 20.41K | 168.73M |
| Common Stock Repurchased | 0 | (5.52M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 34.34M | 76.97K | 59.66M | (286.04K) | (11.96K) |
| Financing Cash Flow | 35.89M | 1.05M | 66.77M | (1.17M) | 168.3M |
| Effect of Forex Changes | 0 | 0 | 18.14K | (241.2K) | (213.5K) |
| Net Change in Cash | 26.93M | (24.5M) | 41.52M | (47.67M) | 1.6M |
| Free Cash Flow | (8.96M) | (25.63M) | (25.32M) | (34.63M) | (45.71M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$13.3M
+ D&A$3.1M
+ Stock-Based Comp$5.2M
+ Deferred Tax$0
- Working Capital-$3.7M
- Other Non-Cash-$62.7M
= Operating Cash Flow-$44.8M
- Capex-$933.2K
= Free Cash Flow-$45.7M
Analysis
FY2025 free cash flow is -$45.7M. FCF conversion is -344.4% of net income. Operating cash flow was -$44.8M, with capex of -$933.2K. The largest bridge item is Other Non-Cash at -$62.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 25-NSE | 25-NSE filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 | |
| 424B3 | 424B3 filing | Aug 21, 2026 |
Does SABS generate free cash flow?
SAB Biotherapeutics, Inc. (SABS) generated -$45.71M of free cash flow in fiscal 2025.
How much operating cash flow does SABS produce?
Operating cash flow was -$44.78M, before capital expenditures of $933,151.00.
Continue the stock analysis
Jump to another research area for this company.